UNI-BIO GROUP (00690) announced its interim results for 2025, reporting revenue of HK$310 million, representing a 13.4% year-over-year increase. Net profit reached HK$75.955 million, up 12.7% compared to the same period last year, with basic earnings per share of 1.27 HK cents.

The period's profit growth was primarily driven by the group's sales channel expansion, increasing demand for Bogutai®, and sustained market attention toward the group's listed pharmaceutical products. This performance also reflects the strategic effectiveness of the group's focus on operational efficiency, stringent cost control, and precise commercial execution, further solidifying its trajectory of sustained profit growth and long-term value creation.